Skip to Content
7

Vertex Pharmaceuticals

Yoon S. Byun—The Boston Globe/Getty Images

    Vertex got its start ­making a hepatitis C drug, but it has more recently homed in on medicine that treats symptoms of cystic fibrosis, a genetic disease that afflicts 75,000 people worldwide. Its two bestselling drugs, Orkambi and Kalydeco, account for 87% of its $2.6 billion in revenue. And in February, Vertex received approval of a third CF drug, Symdeko, which earned $186 million in its first quarter on the market—more than twice what analysts expected. The success of the drugs has helped Vertex more than double its revenue in three years.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score4.6
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Jeffrey M. Leiden
    Websitehttp://www.vrtx.com
    Employees2,300
    HQ Location
    Boston
    Revenues ($M) (Past 12 Months)$2,623
    Profits ($M) (Past 12 Months)$415
    Market Value as of Oct. 10, 2018 ($M)$45,088